IMODIUM QUICK DISSOLVE 2 MG
LOPERAMIDE HYDROCHLORIDE : 2 MG · DIN 02230542 · MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
Health Canada status: MARKETED
What is IMODIUM QUICK DISSOLVE?
IMODIUM QUICK DISSOLVE 2 MG contains LOPERAMIDE HYDROCHLORIDE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02230542, held by MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC, supplied as TABLET (ORALLY DISINTEGRATING) for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Mar-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is IMODIUM QUICK DISSOLVE used for?
IMODIUM® (loperamide hydrochloride) is indicated: • as an adjunct to rehydration therapy for the symptomatic control of acute non-specific diarrhea • for chronic diarrhea associated with inflammatory bowel disease • for reducing the volume of discharge for ileostomies, colostomies and other intestinal resections. Treatment of diarrhea with IMODIUM® is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate (or when indicated).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02230542 |
|---|---|
| Brand name | IMODIUM QUICK DISSOLVE |
| Generic / active ingredient | LOPERAMIDE HYDROCHLORIDE : 2 MG |
| Manufacturer | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC |
| Strength | 2 MG |
| Dosage form | TABLET (ORALLY DISINTEGRATING) |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A07DA03 LOPERAMIDE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Mar-2026 |
How is it administered?
Adults: Initial 4 mg, then 2 mg after each loose stool. Max 16 mg/day. Children (6-12): Dose based on weight/age. Quick Dissolve/LIQUI-GELS not for children <6 years.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
IMODIUM® Quick Dissolve tablets: one (10 tablet), two (20 tablet), or five (50 tablet) blister strips. IMODIUM® Calming Liquid: 240 mL. IMODIUM® LIQUI-GELS® capsules: 6, 12, 24, 36 and 60 capsules.
Contraindications
Hypersensitivity; children <2 years; cases where constipation/inhibition of peristalsis must be avoided; acute dysentery; acute ulcerative colitis; bacterial enterocolitis; pseudomembranous colitis.
Warnings and precautions
Treatment is symptomatic only. Discontinue if no improvement in 48h (acute). High doses may lead to serious cardiac events/arrhythmias. May cause tiredness, dizziness, or drowsiness.
What can be used instead?
Other Canadian products sharing ATC code A07DA03 LOPERAMIDE. 14 of 39 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DIARRHEA RELIEF | 2 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02248994 |
| DIARRHEA RELIEF | 2 MG | TABLET | VITA HEALTH PRODUCTS INC | MARKETED | DIN 02256452 |
| DIARRHEA RELIEF FAST DISSOLVE | 2 MG | TABLET (ORALLY DISINTEGRATING) | JUNO OTC INC | MARKETED | DIN 02499517 |
| DIARRHEA RELIEF LIQUID GELS | 2 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02553139 |
| DIARRHEA RELIEF LIQUID GELS | 2 MG | CAPSULE | LABORATOIRE RIVA INC. | MARKETED | DIN 02552337 |
| IMODIUM CALMING LIQUID | 2 MG / 15 ML | SOLUTION | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02291800 |
| IMODIUM LIQUI-GELS | 2 MG | CAPSULE | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02376016 |
| JAMP LOPERAMIDE | 2 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02544989 |
| LOPERAMIDE-2 | 2 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02225182 |
| PMS-LOPERAMIDE - CAPLET 2MG | 2 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02228351 |
Who else supplies LOPERAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LOPERAMIDE appears in 37 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.